Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review
Fig 7
Pooled estimates and 95% CI for subgroup analyses.
(A) objective response rate (ORR) and (B) grade 3–5 adverse events (G3–5 AEs) by therapy, funding source, and phase number. Asterisks indicate statistical significance (p < 0.05).
doi: https://doi.org/10.1371/journal.pbio.2000487.g007